Angitia Biopharmaceuticals Announces $120 Million Series C Financing - Financing led by Bain Capital Life Sciences with significant participation from existing and new investors - Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline...

Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...

Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024 WOODLAND HILLS, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...

Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024 Angitia announces multiple presentations at ASBMR.